CD38 and Miyoshi myopathy: ,22 High TRC score was associated with poor outcome in 4 independent cohorts of newly diagnosed patients with MM (UAMS, TT2 cohort, n = 345; HM, n = 206; CoMMpass, n = 674; Hovon, n = 282) treated with HDT and ASCT (Figure 1B; supplemental Figure 1A-B) and also in a cohort of patients at relapse treated with the anti-CD38 mAb daratumumab (Figure 1B).